Overview
My lab website has a fuller description of my research activities: https://sites.duke.edu/taylorlab/.
I am principally interested in field and translational studies of falciparum malaria. These interests fall along several lines:
1) Molecular Epidemiology. With partners principally in Kenya, we use community-based cohorts coupled with advanced genetic sequencing and immuno-epidemiologic approaches to better understand parasite transmission, clinical disease, and immunity. The goals of these studies are to identify opportunities to intervene at the community level to reduce malaria.
2) Pathogenesis. Severe malaria is a lethal disease; it is the cause of most of the 400,000 malaria deaths annually in African children. In these children, sickle-trait hemoglobin confers >90% protection from severe, life-threatening malaria. We are investigating the molecular genetic correlates of this phenomenon in in vitro and ex vivo systems in order to identify mechanisms by which sickle-trait neutralizes the parasite. By leveraging this naturally-occurring model of malaria protection we hope to ultimately identify druggable targets for future antiparasitic or adjunctive therapies.
3) Clinical trials. In malaria-endemic Africa, high-risk groups that suffer disproportionate malaria morbidity clearly benefit from focused malaria prevention strategies. We have trialed alternate chemoprevention regimens in children with sickle cell anemia in Kenya, and are currently testing in pregnant women in the DRC and Kenya the impact of enhanced screening for parasites early in pregnancy on the outcome of pregnancy. The goal of these projects is to enhance public health guidelines for the routine care of these high-risk groups and reduce the burden of malaria in African children.
The ultimate goals of these translational studies of falciparum malaria in children and pregnant women is to integrate epidemiologic, clinical, and molecular genetic models of disease in order to inform the rational design of medical and public health interventions to reduce the awful burden of malaria.
I am principally interested in field and translational studies of falciparum malaria. These interests fall along several lines:
1) Molecular Epidemiology. With partners principally in Kenya, we use community-based cohorts coupled with advanced genetic sequencing and immuno-epidemiologic approaches to better understand parasite transmission, clinical disease, and immunity. The goals of these studies are to identify opportunities to intervene at the community level to reduce malaria.
2) Pathogenesis. Severe malaria is a lethal disease; it is the cause of most of the 400,000 malaria deaths annually in African children. In these children, sickle-trait hemoglobin confers >90% protection from severe, life-threatening malaria. We are investigating the molecular genetic correlates of this phenomenon in in vitro and ex vivo systems in order to identify mechanisms by which sickle-trait neutralizes the parasite. By leveraging this naturally-occurring model of malaria protection we hope to ultimately identify druggable targets for future antiparasitic or adjunctive therapies.
3) Clinical trials. In malaria-endemic Africa, high-risk groups that suffer disproportionate malaria morbidity clearly benefit from focused malaria prevention strategies. We have trialed alternate chemoprevention regimens in children with sickle cell anemia in Kenya, and are currently testing in pregnant women in the DRC and Kenya the impact of enhanced screening for parasites early in pregnancy on the outcome of pregnancy. The goal of these projects is to enhance public health guidelines for the routine care of these high-risk groups and reduce the burden of malaria in African children.
The ultimate goals of these translational studies of falciparum malaria in children and pregnant women is to integrate epidemiologic, clinical, and molecular genetic models of disease in order to inform the rational design of medical and public health interventions to reduce the awful burden of malaria.
Current Duke Appointments & Affiliations
Professor of Medicine
·
2024 - Present
Medicine, Infectious Diseases,
Medicine
Research Professor of Global Health
·
2024 - Present
Duke Global Health Institute,
University Institutes and Centers
Recent Scholarly Works
Sickle Trait Hemoglobin Does Not Influence Anopheles Biting Rates.
Journal article Am J Trop Med Hyg · June 3, 2026 Children with sickle cell trait (HbAS) are protected against severe and symptomatic Plasmodium falciparum (P. falciparum) malaria. Although several within-host resistance mechanisms have been investigated, it is unknown whether this protection is attributa ... Full text Link to item CiteDo Piperonyl Butoxide Long-Lasting Insecticide Treated Nets Provide Additional Protection Against Malaria Infections Compared with Conventional Nets in an Operational Setting in Western Kenya?
Journal article Am J Trop Med Hyg · January 7, 2026 Malaria control in sub-Saharan Africa has stagnated despite widespread adoption of control measures such as long-lasting insecticidal nets (LLINs). Progress has stalled, in part, because of pyrethroid insecticide resistance, driving the need for retooling ... Full text Link to item CiteThe burden of malaria-attributable maternal anaemia and the impact of preventive treatment across sub-Saharan Africa.
Journal article Nat Health · 2026 Malaria in pregnancy is a major but poorly quantified contributor to maternal anaemia in sub-Saharan Africa. We combined individual-level data on haemoglobin (Hb), gravidity, gestational age and PCR-confirmed Plasmodium falciparum infection from 12,608 pre ... Full text Link to item CiteRecent Grants
PARSEC: Plasmodium falciparum Adaptive Response to Sickle trait Erythrocytes
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2026 - 2031Transdisciplinary Research in Infectious Diseases to Engage Third-year medical students (TRIDENT) R25
Inst. Training Prgm or CMECo-Principal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2025 - 20302/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Center for Advancing Translational Sciences · 2025 - 2030View All Grants
Education
Duke University, School of Medicine ·
2004
M.D.
University of North Carolina, Chapel Hill ·
2003
M.P.H.
Duke University ·
1998
B.S.